Canagliflozin in Children and Adolescents with Type 2 Diabetes Mellitus

Treatment options for children and adolescents with type 2 diabetes mellitus (T2DM) are limited. Canagliflozin, a sodium–glucose cotransporter-2 inhibitor, is approved for T2DM in adults but requires evaluation in younger populations. The objective was to evaluate the efficacy and safety of canagliflozin in children and adolescents with T2DM.